Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for alleged misconduct during the class period from February 28, 2023, to January 10, 2025, with a lead plaintiff deadline set for April 15, 2025 [1]. Allegations Against TransMedics - The complaint alleges that TransMedics engaged in unethical practices, including the use of kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2]. - It is claimed that TransMedics engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight, which increased the risk of regulatory scrutiny [2]. Lead Plaintiff Process - Investors in TransMedics have until April 15, 2025, to seek appointment as a lead plaintiff representative or may choose to remain absent from the class [3]. - The lead plaintiff will represent the interests of all class members and select counsel to direct the litigation [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired TransMedics Group, Inc. (NASDAQ: TMDX) securities between February 28, 2023 and January 10, 2025. TransMedics describes itself as a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. For more information, submit a form, email attor ...

Core Viewpoint - A class action lawsuit has been filed against TransMedics Group, Inc, alleging securities fraud and other unlawful business practices [1][2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 15, 2025 [3]. - The lawsuit follows accusations from U.S. Representative Paul Gosar regarding misconduct, including misappropriation of corporate resources [3]. Group 2: Stock Price Impact - Following the publication of Representative Gosar's letter, TransMedics' stock price dropped by $3.85 per share, or 4.43%, closing at $83.14 on February 23, 2024 [4]. - On January 10, 2025, after Scorpion Capital's report detailing alleged fraudulent practices, the stock price fell by $3.74 per share, or 5.16%, closing at $68.81 [6]. Group 3: Allegations Against TransMedics - Scorpion Capital's report claims TransMedics engaged in fraudulent billing, off-label misuse of devices, and relied on kickbacks for sales [5]. - The report also highlights ongoing investigations by the U.S. Department of Justice and other agencies into Medicare fraud related to organ acquisition costs, along with customer dissatisfaction leading to the discontinuation of device use by prominent transplant centers [5].

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 15, 2025 in the securities class action first filed by the Firm ...

NEW YORK, Feb. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 15, 2025 in the securities class action first filed by the Firm.So w ...

SAN DIEGO, Feb. 16, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired TransMedics Group, Inc. (NASDAQ: TMDX) securities between February 28, 2023 and January 10, 2025. TransMedics describes itself as a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states.For more information, submit a form, email attorney A ...

SAN DIEGO, Feb. 15, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, inclusive (the "Class Period"), have until April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit.  Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit charges TransMedics ...

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 15, 2025 in the securities class action first filed by the Firm ...

Core Viewpoint - TransMedics Group, Inc. is set to release its financial results for Q4 and the full year 2024 on February 27, 2025, after market close, followed by a conference call with management [1] Company Overview - TransMedics is a leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation, headquartered in Andover, Massachusetts [3] - The company was founded to address the need for more and better organs for transplantation, developing technologies to preserve organ quality and assess organ viability prior to transplant [3]

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into TransMedics Group, Inc. (NASDAQ: TMDX) for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Why Did TransMedics’s Stock Drop? TransMedics is a medical technology company that develops systems to preserve and asses ...